Methotrexate Treatment Current Events | Methotrexate Treatment News
|
|
|
Sort By:
Page Views | Date |
Methotrexate treatment for rheumatoid arthritis effective the second time
A second course of methotrexate, the most commonly used drug to treat rheumatoid arthritis, is effective in nearly half of studied patients for whom a previous treatment with the drug was ineffective. view more (2006-02-24)
Survival Benefit For Rheumatoid Arthritis Patients Treated With Methotrexate (p 1173)
The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this week's issue of THE LANCET. Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection,... view more... (2002-04-04)
First multinational study of Tocilizumab reports in
Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement. view more (2007-06-18)
Rheumatoid arthritis could be prevented if the timing is right
Patients diagnosed with 'undifferentiated rheumatoid' arthritis could actually have their disease outlook changed significantly if treatment is given at the right time. view more (2006-06-22)
St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study. view more (2008-04-16)
Genetic Testing For Cell-Proliferation Enzyme Could Improve Treatment Of Acute Lymphoblastic Leukaemia (p 1033)
Authors of a Canadian research letter in this week's issue of THE LANCET describe how genetic testing for an enzyme involved in cancer-cell proliferation could identify patients at an increased risk of poor outcome from acute lymphoblastic leukaemia. The enzyme thymidylate synthase is associated with cell proliferation, and is therefore an... view more... (2002-03-20)
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one... view more... (2008-06-16)
New long-term data suggests Abatacept treatment
New data from the long-term extension of the AIM (Abatacept in Inadequate responders to Methotrexte) trial, announced today at the Annual European Congress of Rheumatology, suggests the selective T-cell co-stimulation modulator abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an... view more... (2006-06-22)
Increased Risk of Skin Cancer for Psoriasis Patients
The risk of squamous cell cancer of the skin is increased in patients treated for psoriasis with ciclosporin in addition to photochemotherapy, conclude authors of a study in this week's issue of The Lancet. Immunosuppressive treatments such as ciclosporin have been associated with an increased risk of skin cancer, although most previous research... view more... (2001-09-26)
Combination drug therapy could substantially improve symptoms of rheumatoid arthritis (pp 670, 675)
The combination of two drugs - both partly effective for rheumatoid arthritis patients when given individually - could be an important development in substantially reducing symptoms and joint destruction for people with rheumatoid arthritis, conclude authors of a study in this week's issue of THE LANCET. Rheumatoid arthritis affects around 1% of... view more... (2004-02-25)
New evidence shows Rituximab halts damage to joints
New data, presented today at the Annual European Congress of Rheumatology show for the first time that a rheumatoid arthritis (RA) treatment, rituximab, is able to significantly inhibit the structural damage to joints caused by RA in patients who have long-standing disease and an inadequate response to one or more TNF (Tumour Necrosis Factor)... view more... (2006-06-23)
30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy. view more (2008-06-16)
New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB). view more (2008-07-23)
Arthritis medications reduce the risk of heart attacks and strokes
Patients prescribed drugs to treat rheumatoid arthritis could be at a reduced risk of heart attacks and strokes, according to a study published today in the open access journal Arthritis Research & Therapy. view more (2008-03-06)
Hypertension and cholesterol medications present in water released into the St. Lawrence River
A study conducted by Université de Montréal researchers on downstream and upstream water from the Montreal wastewater treatment plant has revealed the presence of chemotherapy products and certain hypertension and cholesterol medications. view more (2009-01-27)
Nanoparticles carry cancer-killing drugs into tumor cells
University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells - increasing the drug's cancer-killing activity and reducing its toxic side effects. view more (2005-06-15)
New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to achieve an adequate response to traditional disease modifying agents (DMARDs). view more (2007-11-09)
Bone erosion reduced by denosumab in phase 2 trial
reatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial. view more (2007-06-18)
50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks
At least 50% of recent onset rheumatoid arthritis patients achieve remission (a state free of signs and symptoms) within 36 weeks when following a systematic approach of step-up DMARD treatment in combination with tight control. view more (2008-06-12)
Brewing up potential anti-cancer drugs from green tea
Drinking green tea has a protective effect against some forms of cancer but drinking large amounts can increase the risk of birth defects such as spina bifida - according to previous epidemiological studies. view more (2005-03-14)
|
|
|
|
Sort By:
Page Views | Date |
|
